Clinical

Dataset Information

0

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma


ABSTRACT: This phase I trial studies the side effects and best dose of cixutumumab when given together with everolimus and octreotide acetate in treating patients with advanced low- or intermediate-grade neuroendocrine cancer. Monoclonal antibodies, such as cixutumumab, may find tumor cells and help carry tumor-killing substances to them. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Octreotide acetate may interfere with the growth of tumor cells and slow the growth of neuroendocrine cancer. Giving cixutumumab together with everolimus and octreotide acetate may be a better treatment for neuroendocrine cancer.

DISEASE(S): Neuroendocrine Tumors,Gastrointestinal Neoplasms,Carcinoma,Insulinoma,Pancreatic Insulinoma,Stage Iii Merkel Cell Carcinoma,Stage Iv Merkel Cell Carcinoma,Thyroid Gland Medullary Carcinoma,Carcinoma, Merkel Cell,Regional Digestive System Neuroendocrine Tumor G1,Malignant Carcinoid Syndrome,Lung Carcinoid Tumor,Pancreatic Glucagonoma,Recurrent Pancreatic Neuroendocrine Carcinoma,Metastatic Digestive System Neuroendocrine Tumor G1,Pancreatic Neoplasms,Stomach Neoplasms,Recurrent Merkel Cell Carcinoma,Carcinoid Tumor,Pancreatic Polypeptide Tumor,Paraganglioma,Carcinoma, Medullary,Recurrent Digestive System Neuroendocrine Tumor G1,Gastrinoma,Somatostatinoma,Somatostatin-producing Neuroendocrine Tumor,Carcinoma, Neuroendocrine,Carcinoma, Islet Cell,Glucagonoma,Gastrin-producing Neuroendocrine Tumor,Intestinal Neoplasms

PROVIDER: 2095294 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2047189 | ecrin-mdr-crc
2012-12-12 | E-GEOD-24358 | biostudies-arrayexpress
2013-01-08 | E-MTAB-388 | biostudies-arrayexpress
2019-05-14 | GSE128593 | GEO
2019-05-14 | GSE128592 | GEO
2019-05-14 | GSE128591 | GEO
2012-12-12 | GSE24358 | GEO
| 2097348 | ecrin-mdr-crc
| PRJNA1033353 | ENA
2021-10-09 | GSE185426 | GEO